Perspective

Nature Reviews Cancer 2, 795-803 (October 2002) | doi:10.1038/nrc909

TimelineVEGF and the quest for tumour angiogenesis factors

Napoleone Ferrara1  About the author

Top

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process. The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as anticancer agents. How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression.

Author affiliations

  1. Napoleone Ferrara is at the Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.
    Email: nf@gene.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

RESEARCH
Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice
British Journal of Cancer Original Article (07 Jul 2003)
Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro
British Journal of Cancer Original Article (20 May 2002)
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
The EMBO Journal Article (15 Jul 1999)
VEGF165 requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells
Oncogene Original Article (06 Sep 2001)
See all 13 matches for Research

Extra navigation

Subscribe

Subscribe to Nature Reviews Cancer

Search PubMed for

naturejobs

natureproducts


Advertisement